JAC Advance Access published online on January 7, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh023
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article
1 Department of Molecular Biology and Biochemistry, University
of California, Irvine, CA 92697-3900, USA
* Corresponding author. E-mail: hbernard{at}uci.edu.
Anogenital cancers, in particular cancer of the cervix,
and common, genital and laryngeal warts are primarily caused by
infection with human papillomaviruses. Traditionally, the primary
goal of treatment is to remove the neoplasia by various surgical
approaches; however, all of these have high rates of recurrence.
Only a few non-surgical treatments have found their
way into clinical practice, and none of them is generally recommended
because of side effects, limited efficacy and recurrences. This
article summarizes the research on pharmaceutical and immunological
approaches that may find a place in clinical practice to complement
or replace surgical treatments.
Keywords: cancer of the cervix, warts, interferon, cidofovir,
vaccination
Established and potential strategies against papillomavirus
infections
![]()
CiteULike
Connotea
Del.icio.us What's this?